Medicare drug program fails to monitor prescribers
Ten years ago, a sharply divided Congress decided to pour billions of dollars into subsidizing the purchase of drugs by elderly and disabled Americans. The initiative, the biggest expansion of Medicare since its creation in 1965, proved wildly popular. It now serves more than 35 million people, delivering critical medicines to patients who might otherwise be unable to afford them. Its price tag is far lower than expected. But an investigation by ProPublica has found the program, in its drive to get drugs into patients' hands, has failed to properly monitor safety.
- Providers Lag as Consumers Set Agenda
- ICD-10 Delay Alters Provider, Vendor Prep
- Esther Dyson Launches Population Health Challenge
- Crisis Spurs Healthcare Payment Reform in Arkansas
- Payment Reform Naysayers 'Better Wake Up'
- Look Beyond Nurse-Patient Ratios
- HIT Leaders Want Flexibility, Transparency from Next HHS Chief
- Reduce Readmissions by Activating Patients to Do 'Self-Care'
- As Hospitalist Patient Loads Rise, So Do Hospital Costs
- Hospital Groups Back NQF Report on Patient Sociodemographics